FR2439017A1 - Artificial cerebrospinal fluid - contg. a hexose and alkali or alkaline earth metal salts in sufficient quantity to lower the freezing point - Google Patents

Artificial cerebrospinal fluid - contg. a hexose and alkali or alkaline earth metal salts in sufficient quantity to lower the freezing point

Info

Publication number
FR2439017A1
FR2439017A1 FR7829621A FR7829621A FR2439017A1 FR 2439017 A1 FR2439017 A1 FR 2439017A1 FR 7829621 A FR7829621 A FR 7829621A FR 7829621 A FR7829621 A FR 7829621A FR 2439017 A1 FR2439017 A1 FR 2439017A1
Authority
FR
France
Prior art keywords
hexose
alkali
alkaline earth
freezing point
sufficient quantity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7829621A
Other languages
French (fr)
Other versions
FR2439017B1 (en
Inventor
Simone Coignard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KabiVitrum SA
Original Assignee
KabiVitrum SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KabiVitrum SA filed Critical KabiVitrum SA
Priority to FR7829621A priority Critical patent/FR2439017A1/en
Publication of FR2439017A1 publication Critical patent/FR2439017A1/en
Application granted granted Critical
Publication of FR2439017B1 publication Critical patent/FR2439017B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

An artificial cerebro-spinal fluid (I) contains 0.3-0.9 g/litre of a hexose and mineral salts in sufficient quantity to lower the freezing point, or cryoscopic DELTA t, by 0.5 to 0.7 degrees C. The hexose is pref. glucose and/or levulose and the mineral salts are alkali or alkaline earth cations with chloride, sulphate, bicarbonate or phosphate anions. The total wt. of mineral salts is 6-12 g/l. (I) is used (i) to prevent dessication of nervous tissue during surgery, (ii) as a vehicle for medicaments, which act on the cortex or marrow, (iii) for injection into the spinal cord when measuring intracranial pressure, (iv) for dialysis of human cerebro-spinal fluid during auto-immune diseases, (v) to inject cranial radiographic contrast media, and (vi) as a solvent for injectable proteins.
FR7829621A 1978-10-18 1978-10-18 Artificial cerebrospinal fluid - contg. a hexose and alkali or alkaline earth metal salts in sufficient quantity to lower the freezing point Granted FR2439017A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7829621A FR2439017A1 (en) 1978-10-18 1978-10-18 Artificial cerebrospinal fluid - contg. a hexose and alkali or alkaline earth metal salts in sufficient quantity to lower the freezing point

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7829621A FR2439017A1 (en) 1978-10-18 1978-10-18 Artificial cerebrospinal fluid - contg. a hexose and alkali or alkaline earth metal salts in sufficient quantity to lower the freezing point

Publications (2)

Publication Number Publication Date
FR2439017A1 true FR2439017A1 (en) 1980-05-16
FR2439017B1 FR2439017B1 (en) 1982-10-22

Family

ID=9213876

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7829621A Granted FR2439017A1 (en) 1978-10-18 1978-10-18 Artificial cerebrospinal fluid - contg. a hexose and alkali or alkaline earth metal salts in sufficient quantity to lower the freezing point

Country Status (1)

Country Link
FR (1) FR2439017A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308459A (en) * 1991-03-07 1994-05-03 Baxter Diagnostics Inc. Biosynthetic cerebrospinal fluid control and method of use
EP1875919A1 (en) * 2005-04-19 2008-01-09 Otsuka Pharmaceutical Factory, Inc. Artificial cerebrospinal fluid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB486880A (en) * 1935-12-14 1938-06-13 Arthur Percival Masters Improved game apparatus
US3067098A (en) * 1959-11-02 1962-12-04 Baxter Don Inc Intravenous nourishment of patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB486880A (en) * 1935-12-14 1938-06-13 Arthur Percival Masters Improved game apparatus
US3067098A (en) * 1959-11-02 1962-12-04 Baxter Don Inc Intravenous nourishment of patients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA1975 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308459A (en) * 1991-03-07 1994-05-03 Baxter Diagnostics Inc. Biosynthetic cerebrospinal fluid control and method of use
EP1875919A1 (en) * 2005-04-19 2008-01-09 Otsuka Pharmaceutical Factory, Inc. Artificial cerebrospinal fluid
US20090092681A1 (en) * 2005-04-19 2009-04-09 Otsuka Pharmceutical Factory ,Inc. Artificial cerebrospinal fluid
EP1875919A4 (en) * 2005-04-19 2012-09-26 Otsuka Pharma Co Ltd Artificial cerebrospinal fluid
US8409624B2 (en) * 2005-04-19 2013-04-02 Otsuka Pharmaceutical Factory, Inc. Artificial cerebrospinal fluid

Also Published As

Publication number Publication date
FR2439017B1 (en) 1982-10-22

Similar Documents

Publication Publication Date Title
James et al. Comparison of the reflex vasomotor responses to separate and combined stimulation of the carotid sinus and aortic arch baroreceptors by pulsatile and non‐pulsatile pressures in the dog
Adamsons et al. The innocuousness of amniotic fluid infusion in the pregnant rhesus monkey
CA2000493A1 (en) Blood perfusion system and tube means used therein
Petruk et al. Cerebral blood flow following induced subarachnoid hemorrhage in the monkey
Barcroft et al. IV. Effects of functional activity in striated muscle and the submaxillary gland
Root et al. Disturbances in the chemistry and in the acid-base balance of the blood of dogs in hemorrhagic and traumatic shock
Kaltreider et al. The effect of epinephrine on the volume of the blood
FR2439017A1 (en) Artificial cerebrospinal fluid - contg. a hexose and alkali or alkaline earth metal salts in sufficient quantity to lower the freezing point
Tobin Varying role of extracellular electrolytes in metabolic acidosis and alkalosis
Winkelmann et al. Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5‐hydroxytryptamine
Henderson et al. Acapnia and Shock: VIII. The Veno-Pressor Mechanism
DeFeo et al. Histological examination of kaolin-induced hydrocephalus: its implications in the therapy of animals with experimentally induced hydrocephalus
Knopp et al. Effect of Diamox on cerebrospinal fluid pressure of cat and monkey
STEINHORN et al. Pharmacodynamic response to ionized calcium during acute sepsis
Bourke et al. Mediated transport of chloride from blood into cerebrospinal fluid
Vanhoutte et al. The Cardiovascular Adaptation of the Dog to Muscular Exercise.–Role of the Arterial Pressoreceptors
Adams et al. Regional hypothermia of the brain
Leung et al. Blood flow limitation of stimulated gastric acid secretion in the rat
Prentice et al. A study of the relationship between radioactive sodium clearance and directly measured blood flow in the biceps muscle of the dog
Murray Jr PHYSIOLOGICAL ONTOGENY: A. Chicken Embryos. XI. The pH, Chloride, Carbonic Acid, and Protein Concentrations in the Tissues as Functions of Age.
Angelos et al. Arterial blood gases during cardiac arrest: markers of blood flow in a canine model
Farrell et al. Microvascular pressures in gill filaments of lingcod (Ophiodon elongatus)
Ikeyama et al. The analysis of the intracranial pressure by the concept of the driving pressure from the vascular system
Gissen Toxicity of Local Anaesthetics in Obstetrics II: Chloroprocaine—Research and Clinical Aspects
Torbati et al. Effect of Hemorrhagic Hypotension on CBF and ICP After Brain Missile Wounding in Anesthetized Paralyzed Cats

Legal Events

Date Code Title Description
ST Notification of lapse